RGX-104 hydrochloride

• CAT Number: I012057
• CAS Number: 610318-03-1
• Molecular Formula: C34H34Cl2F3NO3
• Molecular Weight: 632.545
• Purity: ≥95%
• Storage: Room temperature
• Related CAS: 610318-54-2(free base)
• IUPAC Name: 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid;hydrochloride
• InChI: InChI=1S/C34H33ClF3NO3.ClH/c1-24(18-19-42-29-16-8-10-25(20-29)21-32(40)41)39(22-28-15-9-17-31(33(28)35)34(36,37)38)23-30(26-11-4-2-5-12-26)27-13-6-3-7-14-27;/h2-17,20,24,30H,18-19,21-23H2,1H3,(H,40,41);1H/t24-;/m1./s1
• InChIKey: LCMIYQOJZLRHTO-GJFSDDNBSA-N
• SMILES: CC(CCOC1=CC=CC(=C1)CC(=O)O)N(CC2=C(C(=CC=C2)C(F)(F)F)Cl)CC(C3=CC=CC=C3)C4=CC=CC=C4.Cl

RGX-104 hydrochloride (CAT: I012057) is an orally bioavailable agonist of the liver X receptor beta (LXRβ), which is a nuclear receptor involved in the regulation of lipid metabolism and inflammation. By activating LXRβ, RGX-104 modulates gene expression involved in lipid homeostasis, immune response, and inflammation. This activation leads to increased cholesterol efflux, reduced inflammation, and improved immune response. RGX-104 has shown potential therapeutic effects in preclinical studies, suggesting its utility in the treatment of various diseases, including cancer, autoimmune disorders, and metabolic diseases.

Overview of Clinical Research

Originator: GlaxoSmithKline
Developer: Rgenix
Class: Antineoplastics; Immunotherapies; Small molecules
Mechanism of Action: Liver X receptor agonists
Orphan Drug Status: Yes – Malignant melanoma; Glioblastoma; Ovarian cancer

New Molecular Entity: Yes

Highest Development Phases: Phase I Lymphoma; Solid tumours